Navigation Links
A vaccine that works in newborns?
Date:3/4/2013

BOSTON, March 4, 2013 /PRNewswire-USNewswire/ -- The underdeveloped immune systems of newborns don't respond to most vaccines, leaving them at high risk for infections like rotavirus, pertussis (whooping cough) and pneumococcus. Researchers at Boston Children's Hospital have identified a potent compound that activates immune responses in newborns' white blood cells substantially better than anything previously tested, and that could potentially make vaccines effective right at birth.

The ability to immunize babies at birth—rather than two months of age, when most current vaccination series begin—would be a triumph for global health. Worldwide, each year, infections kill more than 2 million infants under 6 months old. In resource-poor countries, birth may be the only time a child has contact with a health care provider.

While newborns lack most aspects of the immune response, researchers led by Ofer Levy, MD, PhD, of the Division of Infectious Disease at Boston Children's have shown that their white blood cells do have one receptor that responds strongly to stimulation, known as Toll-like receptor 8 (TLR 8). In their new work, published March 4 by the online open-access journal PLoS ONE, they tested a panel of synthetic small-molecule compounds that specifically target TLR8, known chemically as benzazepines.

The compounds, provided by VentiRx Pharmaceuticals (Seattle, WA), potently stimulate the human immune system and are in clinical trials in patients with certain cancers.

Tested in Levy's lab, one benzazepine, VTX-294, produced a strong immune response in white blood cells from newborns (taken from cord blood samples) as well as whole blood from adults. It induced robust production of cytokines—chemicals that rally the immune response—and proved at least 10 times more potent than the best activator of TLR8 known previously.

"The response was not only equal to that in adults, but VTX 294 was sometimes actually more effective in newborns than adults," notes Levy, the study's senior investigator.

The compound also triggered production of so-called co-stimulatory molecules that enhance immune responses. Moreover, even very low concentrations of VTX-294 strongly activated antigen-presenting cells, a type of white blood cell whose activation induces immune memory—key to effective responses to vaccines.

Toll-like receptors (TLRs), first identified in humans about two decades ago, are part of the innate (rapid) immune response that provides our first defense against infections. Ten types of TLRs are known, and TLR stimulators have begun to be added to vaccines as adjuvants. The main one, monophosphoryl lipid A (MPLA), stimulates TLR4 and is used in the human papillomavirus vaccine Cervarix. However, in a recent clinical trial published in The New England Journal of Medicine, a malaria vaccine with MPLA failed to elicit a sufficient immune response in infants.

With encouraging results in cells from human newborns, Levy and colleagues now hope to formulate VTX 294 or a similar TLR8 stimulator for testing as a vaccine adjuvant in newborn primates, a model in which the lab has expertise, and whose responses to TLR8 closely resemble humans'.

"This one receptor seems to lead to more adult-like responses—immediate, short-term responses that are more appropriate for fighting infections," says David Dowling , PhD, co-first author on the study. "We're excited about the benzazepines because they are already in the clinical pipeline. That advances the potential for using them in a clinical study in human newborns, once they have been proven safe in animal studies."

The current study was supported by VentiRx Pharmaceuticals and grants from the National Institutes of Health (R01 18AI100135-01). Dowling and Zhen Tan , MD of the Division of Infectious Diseases at Boston Children's Hospital share first authorship on the paper. Coauthors were Zofia Prokopowicz , PhD, and Christine Palmer , PhD, of Boston Children's, and Maura-Ann Matthews , PhD, Gregory Dietsch , PhD, DABT, and Robert Hershberg , MD, PhD, of VentiRx.

For further background on the Levy lab's work, see this blog post.

Boston Children's Hospital is home to the world's largest research enterprise based at a pediatric medical center, where its discoveries have benefited both children and adults since 1869. More than 1,100 scientists, including nine members of the National Academy of Sciences, 11 members of the Institute of Medicine and 11 members of the Howard Hughes Medical Institute comprise Boston Children's research community. Founded as a 20-bed hospital for children, Boston Children's today is a 395-bed comprehensive center for pediatric and adolescent health care grounded in the values of excellence in patient care and sensitivity to the complex needs and diversity of children and families. Boston Children's also is a teaching affiliate of Harvard Medical School. For more information about research and clinical innovation at Boston Children's, visit: http://vectorblog.org/.

CONTACT:
Erin Tornatore
Boston Children's Hospital
617-919-3110 | erin.tornatore@childrens.harvard.edu


'/>"/>
SOURCE Boston Children's Hospital
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Vaccine Manufacturing Technology and Services: World Market 2013-2023
2. New Bioterrorism Vaccine Gets First Test In Humans
3. Cytos VLP Platform is Basis for Phase 1 Clinical Trial with Anti-IgE Vaccine
4. Generex Points to Potential of Antigen Express Technology Platform beyond Its AE37 Breast Cancer Vaccine
5. Targovax AS Announces First Patient Included in Phase I/II Clinical Study With the Therapeutic Cancer Vaccine TG01 in Operable Pancreatic Cancer
6. Research on Chinas Animal Vaccine Industry, 2013-2017
7. Details of HER-2/neu Class I Antigen Licensed by TapImmune published in Journal of Immunology: Antigen is a naturally processed epitope for breast cancer vaccines.
8. Inovios Synthetic Flu Vaccine Doubles Rate of Elderly Subjects Displaying Protective Immune Responses
9. National Institute of Health Awards Contract to Support Use of iBios Proprietary Technology for Improved Anthrax Vaccine
10. OncoSec Medical to Present Data at DNA Vaccines 2012 Conference
11. Axion Health Sponsors Webinar on Vaccine Development Featuring Dengue Fever Case Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Sweden , Mar 23, 2017 ... medicine company, today announced that the English version of the ... website www.neurovive.com .  ... About NeuroVive NeuroVive Pharmaceutical AB ... to the discovery and development of medicines that preserve mitochondrial ...
(Date:3/22/2017)... DUBLIN , Mar. 22, 2017 Research ... Care Devices Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 10.9% over the next ... This industry report analyzes the market estimates and forecasts for all ...
(Date:3/22/2017)... 22, 2017 Under the impetus of ... market size increased year by year at the ... 2021, the market size will maintain the growth ... outnumber RMB140 billion in 2021, thanks to severe ... of biological agents and supporting policies. At ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... ... software solution, iCode Assurance, at HCCA’s 21st annual Compliance Institute on March 26-28 ... coding audit process for all medical chart types with a comprehensive set of ...
(Date:3/23/2017)... ... ... Journey Through Heaven”: the true-life account of a man who faced death and emerged ... for His people. “My Journey Through Heaven” is the creation of published author Earl ... grandchildren living and doing for God as best they can. , Published by Christian ...
(Date:3/23/2017)... ... ... simple and strong explanation of the God’s love. “More Corruption” is the creation of published ... to write a book about Him. , She says, “I’m fed up with mortals misjudging ... Lord God. They have not walked in my shoes and I know they never could ...
(Date:3/22/2017)... ... March 23, 2017 , ... Catalent Pharma Solutions, the ... and consumer health products, today announced that it had won the ‘Clinical Supply ... the Suntec Singapore International Exhibition & Convention Centre, Singapore. The award was presented ...
(Date:3/22/2017)... ... , ... Old School Labs™, makers of the best-selling Vintage line of natural ... Theophane, who trained with Floyd Mayweather, made his professional debut in London in 2003 ... impressive number of wins in contests in Britain, Germany and the U.S. , ...
Breaking Medicine News(10 mins):